SMYD2 and colitis: It has been testified that the Bay‐598 is a highly potent and selective inhibitor for SMYD2, the treating with 50 mg/kg Bay‐598 could substantially reduce the inflammation process in DSS‐induced colitis mice model and the psoriasis mice model (Figure 7D and E).